Peptides sit between small molecules and antibodies: large enough for specific activity, small enough for reproducible synthesis.
Die 20 kanonischen Aminosäuren bilden das Vokabular jeder natürlichen Peptidsequenz. Jede besitzt ein gemeinsames Backbone und unterscheidet sich durch ihre Sidechain.
Non-Standard-Bausteine wie D-Aminosäuren, Hyp oder Aib erweitern Stabilität, Halbwertszeit und Konformationskontrolle.
Bilden den hydrophoben Kern; Pro bricht α-Helices und stabilisiert β-Turns.
π-Stacking und UV-Absorption bei 280 nm, Grundlage der HPLC-Detektion.
Wasserstoffbrücken; Cys ermöglicht Disulfid-Brücken.
Salzbrücken und pH-abhängige Protonierung.
Stabilität, Halbwertszeit und Membranpermeabilität.
Die Peptidbindung entsteht durch Kondensation der α-COOH-Gruppe mit der α-NH₂-Gruppe der nächsten Aminosääure. Das planare Amid-Backbone bestimmt die Konformation.
Φ- und Ψ-Diederwinkel bestimmen Sekundärstruktur. Das Ramachandran-Diagramm visualisiert erlaubte Kombinationen.
Schützt Termini vor Exopeptidase-Abbau.
Proteasen erkennen D-Konfiguration an Spaltstellen nicht.
Head-to-tail oder Disulfid-Brücken stabilisieren die Struktur.
Fettsäure-Anker verlängern die Halbwertszeit über Serumalbumin.
Festphasen-Peptidsynthese (SPPS) verankert die wachsende Kette an einem Polymerharz. Pro Zyklus: Entschützung und Kopplung der nächsten Fmoc-Aminosäure.
Erste Aminosäure am Wang- oder Rink-Amid-Harz. Beladungsdichte 0,2-0,8 mmol/g.
Fmoc-Abspaltung mit Piperidin in DMF.
Aktivierung mit HBTU/HATU oder DIC/Oxyma.
TFA-Spaltung vom Harz und Sidechain-Schutzgruppen.
Festphase, Sequenz wächst am Harz.
Gramm- bis Kilogramm-Maßstab.
Ring-Schließung für Stabilität.
Protease-resistente Konfiguration.
Albumin-Bindung und Verlängerung der HWZ.
Drug-Albumin-Conjugate über Cys-Maleimid.
RP-HPLC auf C18 für Reinheit.
Gefriergetrocknet unter Schutzgas.
Chromatographie, Massenspektrometrie, Schwermetall-Kontrolle und mikrobiologische Sicherheit liefern ein vollständiges Charge-Bild.
Reversed-Phase mit UV-Detektion für Reinheit und Identität.
Molekulargewicht und Fragmentierung.
Schwermetalle auf ppb-Niveau.
Mikrobiologische Sicherheit nach USP.
Our reference catalog is organized around the established research fields of peptide science. Each field links into the filtered study journal and the matching compound catalog.
Incretin and metabolic signaling (GLP-1, GIP, glucagon) — among the most active clinical research areas.
Tissue repair, angiogenesis and regeneration — predominantly preclinical models.
Neuromodulation, cognition and sleep-wake regulation in the CNS.
Cellular senescence, telomere biology and geroprotective peptides.
Skin matrix, collagen signaling and topical formulation research.
Growth-hormone axis and sports-related endocrine research.
Immunomodulation and antimicrobial peptides.
Pharmacological characterization and translational drug research.
This overview places the catalog's compound classes at the level of their known molecular targets — textbook-level and general. It is scientific context for research (RUO), not a product or health claim.
Analogs of incretin hormones bind the G-protein-coupled receptors GLP-1R, GIPR and the glucagon receptor. Research characterizes receptor binding, signal transduction and receptor selectivity of this compound class.
GHRH analogs and selective secretagogues address the hypothalamic-pituitary axis. Studied properties include receptor affinity, secretory pulsatility and half-life-modifying conjugations.
Peptides in this class are examined in preclinical models in the context of angiogenesis, cell migration and actin dynamics. The evidence is predominantly in-vitro and animal.
Mitochondria-derived or -targeting peptides are researched for cardiolipin interaction, electron transport and metabolic homeostasis.
α-MSH analogs and fragments interact with melanocortin receptors (MC1R–MC5R). Research contexts range from photoprotection to inflammation-modulating fragments.
ACTH fragments, tuftsin analogs and sleep-associated peptides are studied in the context of neuroplasticity, neurotransmitter balance and sleep architecture.
Senolytic and regulatory peptides are researched in relation to cellular aging, apoptosis of senescent cells and telomere biology — largely preclinical to date.
A curated selection from the study journal. Each entry links directly to the original publication via its DOI.
The referenced works describe the respective compound class in scientific or clinical research contexts. They are not statements about goodaminos products and do not establish any medical benefit. For research use only (RUO).
Retatrutide 12 mg led to a mean weight loss of 24.2% over 48 weeks, the highest published efficacy among anti-obesity agents.
Semaglutide 2.4 mg/week produced 14.9% mean weight loss vs. 2.4% placebo over 68 weeks, supporting Wegovy approval.
20% reduction in MACE in non-diabetic obese patients, the first obesity therapy with a primary CV outcome.
Tesamorelin 2 mg/day reduced visceral fat by 15.2% vs. placebo in 26 weeks, leading to Egrifta approval.
Pentadecapeptide with documented GI ulcer healing, tendon repair, and VEGF-mediated angiogenesis in preclinical models.
GHK-Cu modulates collagen and reactivates thousands of genes toward youthful expression patterns.
Elamipretide (SS-31) improved 6-minute walk distance by 64.5 m in primary mitochondrial myopathy.
Thymosin alpha-1 as immunomodulator with approved uses in hepatitis B/C in several countries.
Reserved slots for upcoming, verified references. Clearly marked as placeholders — replace with real, DOI-backed studies before go-live (see studies-placeholders.ts).
Meta-Analyse Inkretin-Triagonisten — Referenz ausstehend
Semaglutide · Retatrutide
Sehnen-/Bandregeneration im Tiermodell — Referenz ausstehend
BPC-157
Kognition & Anxiolyse (klinisch) — Referenz ausstehend
Semax · Selank
Geroprotektion & Telomer-Biologie (Review) — Referenz ausstehend
Epithalon
Core concepts from peptide chemistry, analytics and study methodology.
The works listed in the journal are drawn from publicly available, peer-reviewed literature. Where a DOI exists, the entry links directly to the original source for independent review.
Not all evidence is equal: in-vitro and animal models provide mechanistic hints, while randomized controlled human trials carry the strongest weight. Each study card states its type, model and, where applicable, participant count.
References describe the compound class in a research context — they are explicitly not efficacy or health claims about our products. All materials are Research Use Only (RUO).
Cell culture / molecular assays — mechanistic hints.
Preclinical in-vivo data.
Randomized, controlled — strongest single-study evidence.
Synthesis of multiple RCTs — strongest overall statement.
The most common questions about research peptides, analytics and interpretation.
Synthetically produced peptides used as reference and investigational material in laboratory and in-vitro research. They are not intended for human use.
RUO is the regulatory framework for materials supplied strictly for research. No therapeutic claims are made and no medical application is recommended.
The share of the target compound in the total substance, determined by RP-HPLC. Higher purity reduces side peaks and improves experimental reproducibility.
No. The studies describe the respective compound class in scientific research contexts. They are not evidence of a benefit of the reference materials we offer.
A batch-specific analytical document proving the purity, content and identity of a batch — available on request.
